Community nurses administering subcutaneous daratumumab in patients' homes or local clinics was feasible and safe with structured training, clear guidelines, and effective communication, and should be offered as an individualized option rather than a universal replacement for hospital-based treatment.
Most patients preferred home- or local-based administration of subcutaneous daratumumab over hospital-based treatment.
Community nurses and hospital healthcare professionals considered community-based daratumumab administration feasible and safe under certain conditions.
Medication delivery and care coordination created logistical challenges that reduced flexibility for some patients.
Patient-reported quality of life showed no consistent differences between home-based and hospital-based treatment.
Suitability for home administration depends on patient-specific factors.
Successful implementation of community-based daratumumab requires standardized training, clear roles, reliable communication, and efficient workflows.
This study looked at whether community nurses in Denmark could safely give a subcutaneous (under-the-skin) injection of daratumumab, a multiple myeloma treatment, in patients' homes or local health clinics instead of at the hospital. Researchers interviewed 19 patients, 9 community nurses, and 4 hospital professionals, and also measured patients' quality of life with a standard questionnaire. Most patients preferred getting treatment at home or locally, saying it was more comfortable, saved travel, and made life feel more normal. Nurses and hospital staff thought the approach was workable and safe as long as there was good training, clear guidelines, and good communication. Some patients found that delays in medication delivery and coordination problems reduced the flexibility they had hoped for. Quality-of-life scores did not differ in any consistent way between home and hospital treatment. This research suggests that home-based daratumumab can be a reasonable option for some patients with multiple myeloma, but not necessarily for everyone. Factors such as how clinically stable a patient is, their cognitive function, and their personal preferences and routines matter. The study is small and mostly qualitative, so it shows feasibility and patient and staff views rather than proving effects on health outcomes.
Jannie K, Tine R, Brochstedt D, Thomas L. (2026). Bringing Treatment Home: Daratumumab Administration by Danish Community Nurses in Multiple Myeloma-A Mixed-Method Study.. Home healthcare now. https://doi.org/10.1097/NHH.0000000000001476